Elafibranor for previously treated primary biliary cholangitis (TA1016)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 November 2024
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 June 2020
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 January 2020
Obeticholic acid for treating primary biliary cholangitis (TA443)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2017
Everolimus for preventing organ rejection in liver transplantation (TA348)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2015
Seladelpar for previously treated primary biliary cholangitis ID6429Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 September 2025
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
OrganOx metra for liver transplant [ID5116]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC